Scopus
YÖKSİS Eşleşti
The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema
Cutaneous and Ocular Toxicology · Ocak 2017
YÖKSİS Kayıtları
The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema
Cutaneous and Ocular Toxicology · 2016 SCI-Expanded
PROFESÖR BANU TURĞUT ÖZTÜRK →
The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema
Cutaneous and Ocular Toxicology · 2016 SCI-Expanded
PROFESÖR ŞABAN GÖNÜL →
The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema
Cutaneous and Ocular Toxicology · 2016 SCI-Expanded
PROFESÖR ŞABAN GÖNÜL →
Makale Bilgileri
DergiCutaneous and Ocular Toxicology
Yayın TarihiOcak 2017
Cilt / Sayfa36 · 5-8
Scopus ID2-s2.0-84959045318
Özet
Objective: To investigate the effect and safety of intravitreal injection (IVI) of bevacizumab and ranibizumab on corneal endothelial cell count and morphology in patients with diabetic macular edema. Materials and methods: A total of 60 eyes from 60 consecutive patients who received 0.5 mg/0.05 ml IVIs of bevacizumab (n = 30, IVB group) or 1.25 mg/0.05 ml ranibizumab (n = 30, IVR group) for three consecutive months were investigated prospectively. Specular microscopy was performed to evaluate endothelial cell count, the percentage of hexagonal cells (pleomorphism), and the coefficient of variation of the cell size (polymegathism); optical biometry was performed to evaluate central corneal thickness. Results before injection and 1 month after the first and third injections were compared. Results: The groups were matched for age (p = 0.11) and gender (p = 0.32). There was no significant difference in endothelial cell count (IVB group, p = 0.66; IVR group, p = 0.74), pleomorphism (IVB group, p = 0.44; IVR group, p = 0.88) and polymegathism (IVB group, p = 0.21; IVR group, p = 0.24) before injection or 1 month after the first and third injections. There was also no difference in central corneal thickness (IVB group, p = 0.15; IVR group, p = 0.58) before injection or 1 month after the first and third injections. Conclusion: Monthly 1.25 mg/0.05 ml IVIs of bevacizumab or 0.5 mg/0.05 ml of ranibizumab for three consecutive months in the treatment of diabetic macular edema does not affect corneal morphology and has no harmful effects on the endothelium.
Yazarlar (6)
1
Hüseyin Güzel
2
Berker Bakbak
3
Mehmet Talay Koylu
4
Şaban Gönül
5
Banu Turgut Ozturk
ORCID: 0000-0003-0702-6951
6
Şansal Gedik
Anahtar Kelimeler
Bevacizumab
corneal endothelial count
diabetic macular edema
ranibizumab
specular microscopy
vascular endothelial growth factor
Kurumlar
Selçuk Üniversitesi
Selçuklu Turkey
Tatvan Military Hospital
Bitlis Turkey
Tatvan State Hospital
Bitlis Turkey
Metrikler
12
Atıf
6
Yazar
6
Anahtar Kelime